Target intelligence / Profile preview

Sodium-coupled neutral amino acid transporter 2 (SLC38A2) (SNAT2)

Target
SNAT2
Molecular classification
Transporter, Solute carrier family 38, System A amino acid transporter
01

Overview

Sodium-coupled neutral amino acid transporter 2 (SLC38A2), commonly known as SNAT2, is a member of the solute carrier family 38 that mediates the concentrative uptake of small neutral amino acids, with a high preference for L-alanine and L-glutamine. It functions as an electrogenic symporter, utilizing the sodium gradient across the plasma membrane to drive amino acids into the cell, where they serve as biosynthetic precursors and signaling molecules. In the context of oncology, SLC38A2 is frequently upregulated in nutrient-stressed tumor environments, such as pancreatic ductal adenocarcinoma and ARID1A-mutant ovarian cancer, to facilitate the scavenging of environmental alanine from the stroma. This metabolic dependency, often referred to as the "alanine niche," supports mitochondrial metabolism and fuels the tricarboxylic acid (TCA) cycle through anaplerosis. Pharmacological inhibition of SLC38A2 leads to a metabolic crisis characterized by depleted intracellular alanine and glutamine levels, resulting in the suppression of mTORC1 signaling and impaired tumor proliferation. Consequently, SLC38A2 is considered a promising therapeutic target for restricting nutrient access in aggressive and metabolically reprogrammed cancers.

Other names
SNAT2System A transporter 2ATA2SAT2Solute carrier family 38 member 2Amino acid transporter A2Alanine transporter
02

Biological functions

Amino acid transportNutrient sensingmTORC1 activationCell growth regulationpH regulationOsmoregulation
03

Disease associations

Cancer (Pancreatic ductal adenocarcinoma)Cancer (Ovarian clear cell carcinoma)Cancer (Breast cancer)Metabolic disordersNeurodegenerative disease
04

Safety considerations

Potential toxicity to normal tissues with high amino acid demand (e.g., liver, brain)Impact on blood-brain barrier nutrient transportPotential for metabolic compensation by alternative transporters (e.g., SLC1A5, SLC38A1)
05

Interacting drugs

alpha-Methylamino-isobutyric acid (MeAIB)

3 more in the full profile.

06

Biomarkers

SLC38A2 expression (IHC/mRNA)ARID1A mutation statusGPT2 expressionIntracellular alanine levels18F-labeled amino acid PET imaging

Beyond the preview

Go deeper on Sodium-coupled neutral amino acid transporter 2 (SLC38A2) (SNAT2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Sodium-coupled neutral amino acid transporter 2 (SLC38A2) (SNAT2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call